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Background: F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising modality for detecting
active lesions of cardiac sarcoidosis (CS). However, determining whether 18F-FDG uptake in the myocardium is
physiological is challenging due to metabolic shift in myocardial cells. Although methods for inhibiting physiological
myocardial 18F-FDG uptake have been proposed, no standard methods exist. This study therefore aimed to compare
the effect of an 18-h fast (long fasting (LF)) with heparin loading plus a 12-h fast (HEP) before 18F-FDG PET scan.
Methods: We analyzed the effects of LF and HEP on the inhibition of physiological myocardial 18F-FDG uptake in
healthy subjects (18 in HEP and 19 in LF) and in patients with known or suspected CS (96 in HEP and 69 in LF). In CS,
the lower uptake of 18F-FDG in the myocardium was evaluated. A visual four-point scale was used to assess myocardial
18F-FDG uptake in comparison with hepatic uptake (1 lower, 2 similar, 3 somewhat higher, 4 noticeably higher).
Results: Myocardial 18F-FDG uptake was 1.68 ± 1.06 in LF and 3.17 ± 1.16 in HEP in healthy subjects (p < 0.0001),
whereas it was 1.48 ± 0.99 in LF and 2.48 ± 1.33 in HEP in CS patients (p < 0.0001). Logistic regression and regression
trees revealed the LF was the most effective in inhibiting myocardial 18F-FDG uptake. In addition, serum free fatty acid
levels on intravenous 18F-FDG injection were a possible biomarker.
Conclusions: LF is effective in inhibiting myocardial 18F-FDG uptake, and consequently, it could be useful for
evaluating active lesions of CS in 18F-FDG PET images.
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Detecting and managing cardiac sarcoidosis (CS) is chal-
lenging even for expert physicians. The Japanese Ministry
of Health and Welfare has published guidelines for diag-
nosing CS [1], while The Joint Statement of the American
Thoracic Society, the European Respiratory Society, and
the World Association for Sarcoidosis and Other Granu-
lomatous Disorders have proposed a definition of CS [2].
However, there is no convincing consensus on the optimal
methods for disease detection, monitoring, and treatment.* Correspondence: moroi@med.toho-u.ac.jp
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in any medium, provided the original work is p18F-fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) is a promising modality for detecting ‘active’
lesions in various inflammatory cardiovascular diseases,
including cardiac involvement of sarcoidosis, myocarditis,
and vascular diseases such as Takayasu's arteritis, giant
cell arteritis, and atherosclerosis [3-5]. However, assessing
inflammatory cardiomyopathies using 18F-FDG PET can be
challenging because the radiotracer accumulates in normal
myocardium, a phenomenon known as physiological up-
take; this is problematic because the myocardial uptake
of 18F-FDG is heterogeneously based on metabolic shifts in
myocardial cells [6-8].
Methods proposed for the inhibiting increased 18F-FDG
uptake in myocardial physiological cells include heparin,
long fasting, and dietary carbohydrate restriction befores an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Morooka et al. EJNMMI Research 2014, 4:1 Page 2 of 11
http://www.ejnmmires.com/content/4/1/1the scan [4,5,9-15]. These methods are believed to be
associated with reduced blood insulin and increased
circulating free fatty acid (FFA) levels; however, no
study has determined which of these methods is the
most appropriate. The aim of the present study was to
assess the effects of an 18-h fast (long fasting (LF)) on
inhibiting physiological myocardial 18F-FDG uptake com-
pared with heparin loading plus a 12-h fast (HEP) in
healthy subjects and patients with known or suspected CS.
Methods
Subjects
Healthy subjects had no history of cardiac disease or risk
factors, a body mass index (BMI) of <30, no diabetes mel-
litus, no history of illness, and normal electrocardiography
findings. Eighteen healthy subjects underwent 18F-FDG
PET with an intravenous injection of heparin (50 IU/kg)
15 min before 18F-FDG injection with fasting for 12 h
before 18F-FDG PET scan (HEP group), and 19 subjects
were not injected with heparin but they fasted for a
minimum of 16 h (LF group) (Figure 1). FDG PET in
normal volunteers of HEP group was performed from
February 26, 2009 to October 27, 2010, and that of LF
group was done from February 21, 2013 to July 18, 2013.
In the 18 HEP subjects, blood samples for measuring
plasma FFA levels were obtained immediately beforeHeparin




















Figure 1 Protocol of 18F-FDG PET/CT with (A) and without (B) heparin
the injection of 18F-FDG, and the can commenced 60 min after 18F-FDG in
injection and 15 and 75 min after heparin injection in health subjects with
with no heparin loading plus fasting for a minimum of 16 h (LF group), ve(baseline (FFA0)) and 15 min after heparin injection
(FFA15). In 9 of the 18 subjects, additional blood samples
were obtained before starting the scan, and insulin levels
were measured (FFA levels 75 min after heparin injection
(FFA75), baseline insulin levels (Ins0), insulin levels
15 min after heparin injection (Ins15), insulin levels
75 min after heparin injection (Ins75)) (Figure 1).
In patients with known or suspected CS, 18F-FDG PET
with HEP was performed between January 2009 to June
2012, and 18F-FDG PET with LF was performed between
July 2012 and July 2013. Consequently, a total of 96 patients
in the HEP group and 69 patients in the LF group were
included in the study. Patients with histological (or clinical)
diagnosis of extra-cardiac sarcoidosis, with or without
cardiac symptoms, were enrolled in the study. Patients
who had not been diagnosed with extra-cardiac sarcoidosis
but were suspected of having the condition based on
clinical data (e.g., a 55-year-old female with unexplained
sustained second- or third-degree atrioventricular block
or with sustained monomorphic ventricular tachycardia)
were also included in this study [1,16]. The guidelines of the
Japanese Society of Sarcoidosis and Other Granulomatous
Disease are presented in Table 1. For patients in the HEP
group, the blood samples at baseline were collected
after a 12-h fast for measuring fasting blood glucose











loading. Heparin (50 IU/kg) was intravenously injected 15 min before
jection. Venous blood sampling was performed 15 min before 18F-FDG
heparin loading plus a 12-h fast (HEP group). In the healthy subjects
nous blood sampling was performed 15 min before 18F-FDG injection.
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heparin injection, 18F-FDG (370 MBq) was intravenously
injected. For patients in the LF group, the blood samples
at baseline were collected for measuring fasting blood
glucose and FFA0 levels 15 min before intravenous injection
of 18F-FDG (370 MBq).
The Review Board of the National Center for Global
Health and Medicine approved the study protocol. In
accordance with the Declaration of Helsinki, all patients
provided written informed consent before enrollment in
the study.18F-FDG PET scan
PET-computed tomography (CT) (Biograph Siemens 16
and Siemens, Malvern, PA, USA and Discovery PET/CT
600 M, GE, Fairfield, CT, USA) scan of the heart was com-
menced with a 10-min emission scan/bed (one bed
position covering a 16-cm field of view along X-Y-Z axes)
1 h after the intravenous injection of 18F-FDG. A whole-
body PET-CT scan was subsequently performed from the
vertex to the mid-thighs. Attenuation-corrected PET-CT
images were reconstructed using the CT data, and the
PET data were reconstructed using a combination of
FORE and OSEM algorithms (four iterations, eight
subsets; Siemens, Munich) and the 3D-OSEM algorithm
(three iterations, 16 subsets; GE) using a Gaussian filter.Table 1 The Japanese Society of Sarcoidosis and Other Granu
Diagnosis group Guideline
Histological diagnosis group Cardiac sarcoidosis is confirmed when end
epithelioid cell granulomas with a histolog
Clinical diagnosis group Although endomyocardial biopsy specimen
extracardiac sarcoidosis is histologically or c
more than one in six basic diagnostic crite
1. Two or more of the four major criteria ar
2. One of the four major criteria and two o
Major criteria
a. Advanced atrioventricular block
b. Basal thinning of the interventricular sep
c. Positive 67 gallium uptake in the heart
d. Depressed ejection fraction of the left ve
Minor criteria
a. Abnormal ECG findings: ventricular arrhy
CRBBB, axis deviation or abnormal Q-wave
b. Abnormal echocardiography: regional ab
wall thickening)
c. Nuclear medicine: perfusion defect detec
d. Gadolinium-enhanced CMR imaging: del
e. Endomyocardial biopsy: interstitial fibrosi
CMR, cardiac magnetic resonance; CRBBB, complete right bundle branch block; CS,
ventricular contraction.Evaluation of myocardial 18F-FDG uptake
Two experienced cardiologists and two nuclear medicine
specialists determined whether the increased 18F-FDG
uptake in the myocardium was physiological or caused
by active CS. These decisions were based on the findings
of physiological normal images obtained from the
healthy subjects, clinical data such as electrocardiographs,
cardiac echo studies, 201Tl/123I β-methyl-p-iodophenyl-
pentadecanoic acid (BMIPP) single-photon emission
computed tomography image, and cardiac magnetic
resonance imaging.Visually semi-quantitative analysis in healthy subjects or
patients with known or suspected CS
The 18sF-FDG PET images obtained from the healthy
subjects and patients with known or suspected CS in
the HEP and LF groups were visually assessed and
analyzed using a modified four-point scale (grade 1,
myocardial 18F-FDG uptake lower than hepatic uptake;
grade 2, myocardial 18F-FDG uptake similar to hepatic
uptake; grade 3, myocardial 18F-FDG uptake somewhat
higher than hepatic uptake; and grade 4, myocardial 18F-
FDG uptake noticeably higher than hepatic uptake) [17].
Two experienced nuclear medicine physicians who were
unaware of the clinical findings or previous imaging
results independently performed the assessment andlomatous Disorders' guidelines for CS diagnosis (2006)
omyocardial biopsy specimens demonstrate noncaseating
ical or clinical diagnosis of extracardiac sarcoidosis.
s do not demonstrate noncaseating epithelioid cell granulomas,
linically diagnosed and satisfies the following conditions and
ria.
e satisfied.
r more of the five minor criteria are satisfied.
tum
ntricle (<50%)
thmias (ventricular tachycardia, multifocal or frequent PVCs),
normal wall motion or morphological abnormality (ventricular aneurysm,
ted by 201 thallium or 99 mtechnetium myocardial scintigraphy
ayed enhancement of the myocardium
s or monocyte infiltration over moderate grade.
cardiac sarcoidosis; ECG, electrocardiography; PVC, premature
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images is shown in Figure 2, where grade 1 can be recog-
nized as a complete inhibition of physiological uptake.
Quantitative analysis using standardized uptake value in
healthy subjects
In healthy subjects, a region of interest (ROI) was placed
on the maximal accumulation in the basal area, and the
standardized uptake value (SUVmax) was measured. In
patients with known or suspected CS, the SUVmax was not
measured because an SUV in the basal area may be an
active lesion of sarcoidosis; thus, a definite ROI could not
be placed to measure the SUVmax for physiological uptake.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) of
continuous variables, and the Pearson correlation coeffi-
cient and linear regression analysis were used to analyze
the relationship between two variables. The Student's t test
was used to compare variables in healthy subjects and
patients with known or suspected CS. Logistic regression
analysis was used to determine significant predictors
of inhibiting physiological myocardial 18F-FDG uptake.
Finally, regression tree analysis was used to determine the
most significant factor in the clinical setting to inhibit
physiological myocardial 18F-FDG uptake.
Statistical analyses were performed using SPSS software
(SPSS Statistics for Windows, version 20.0, IBM Corp.,
Armonk, NY, USA) for the Student's t test, Pearson
correlation coefficient, and linear regression analysis.(A)
((C)
(
Figure 2 Visual evaluation of myocardial 18F-FDG uptake using a four
uptake (A, grade 1), similar to hepatic uptake (B, grade 2), somewhat highe
uptake (D, grade 4). Grade 1 can be recognized as a complete inhibition oJMP software (version 10, SAS Institute Inc., Cary, NC,
USA) was used for the logistic regression and regression
tree analysis. Statistical significance was defined as p < 0.05.
Results
Differences between HEP and LF and factors for inhibiting
physiological myocardial 18F-FDG uptake in healthy subjects
The characteristics and blood sampling data of the healthy
subjects in the HEP and LF groups are summarized in
Tables 1 and 2, respectively. The fasting blood glucose
levels were <110 mg/dL; there was no difference with
regard to the glucose levels between the HEP and LF
groups. The plasma FFA15 levels increased twofold to
threefold in comparison with the FFA0 levels. However,
the plasma FFA75 levels decreased at the commencement
of scanning (numbers 10 to 18 in Table 2). In many cases,
the Ins15 levels decreased in comparison with the Ins0
levels, and the Ins75 levels further decreased in com-
parison with the Ins15 levels. A correlation between
FFA0 levels and SUVmax was observed in subjects in
the HEP group (r = 0.72, p < 0.05; Figure 3). In contrast,
there was no correlation between SUVmax and FFA15,
FFA75, Ins0, Ins15, or Ins75 levels (Figure 3). An increase
in baseline serum FFA levels may inhibit physiological
myocardial 18F-FDG uptake. Visual semi-quantitative
analysis revealed that only 2 subjects (11.1%) of the 18
subjects in the HEP group had grade 1 physiological
myocardial 18F-FDG uptake.
In contrast, there was no linear correlation between
the FFA0 levels and SUVmax in the subjects in the LFD)
B)
-point scale. Myocardial 18F-FDG uptake was lower than hepatic
r than hepatic uptake (C, grade 3), and noticeably higher than hepatic
f physiological uptake.
Table 2 Healthy volunteers with heparin loading method
No. Age (years) Gender BMI Heparin (IU) FBG (mg/dL) FFA0 FFA15 FFA75 Ins0 Ins15 Ins75 Phy U SUVmax Polar map
pattern(mEq/L) (μU/mL)
1 33 Male 23.4 3,500 99 0.77 2.83 2 2.31 Diffuse
2 34 Male 23.8 4,000 94 0.38 2.34 4 13.04 Basal lateral
3 36 Male 21.6 3,500 90 1.19 1.87 1 2.2
4 38 Female 21.8 2,500 108 0.37 3.96 4 6.56 Basal lateral
5 48 Male 23.4 4,000 104 0.55 2.15 4 6.28 Basal lateral
6 49 Male 21.4 3,500 100 0.38 4.19 4 11.43 Basal lateral
7 58 Male 21.4 3,000 99 0.7 2.03 2 3.39 Basal lateral
8 60 Male 25.3 3,300 106 0.64 2.38 4 5.58 Basal lateral
9 76 Female 23.2 3,000 96 0.64 1.47 2 3.3 Diffuse
10 29 Male 20.8 3,000 82 0.54 1.96 1.2 2.8 2 3.1 4 11.2 Basal lateral
11 32 Female 19.5 3,000 90 0.67 1.21 0.67 4.9 2.1 2.1 4 6.42 Diffuse
12 40 Female 19.5 2,500 102 0.3 1.69 1.06 4 2.5 1.5 4 8.99 Diffuse
13 45 Male 21.53 3,300 102 0.46 1.96 1.52 1.1 1.2 1 3 4.29 Basal lateral
14 47 Female 20 3,000 92 1.24 1.78 1.24 3.3 2.5 1.5 1 1.87
15 52 Male 23.9 4,000 108 0.42 1.25 0.79 4.5 2.6 1.5 4 11.13 Basal lateral
16 54 Female 22 3,000 109 0.67 1.4 1.01 1.5 1.7 0.4 2 2.29 Diffuse
17 55 Female 17.9 2,500 93 0.95 1.7 1.17 3.3 2.8 1.8 4 3.86 Basal lateral
18 62 Female 23.1 3,000 110 0.69 1.62 0.85 1 2.8 1.5 4 7.72 Basal lateral
BMI, body mass index; FBG, fasting blood glucose; FFA0, serum free fatty acid concentration at baseline (normal range 0.10 to 0.81 mEq/L); FFA15, serum free fatty acid concentration 15 min after heparin injection;
FFA75, serum free fatty acid concentration 75 min after heparin injection; Ins0, serum insulin concentration at baseline; Ins15, serum insulin concentration 15 min after heparin injection; Ins75, serum insulin
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15 min after heparin injection 75 min after heparin injection
Figure 3 Association between SUVmax, FFA levels, Ins0, Ins15, and Ins75 in healthy subjects. The upper three graphs show the relationship
between the SUVmax and FFA levels. A significant correlation was observed between the SUVmax and baseline FFA levels immediately before heparin
injection (r = −0.7178, p < 0.05). The bottom three graphs show the relationship between the SUVmax and insulin levels; no correlation was observed.
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the LF group presented with grade 1 physiological myocar-
dial 18F-FDG uptake or complete inhibition of the uptake.
The physiological myocardial 18F-FDG uptake was lower
in subjects in the LF group compared with the HEP group
(Table 4). There were significant differences in physio-
logical myocardial 18F-FDG uptake (3.17 ± 1.16 in HEP,
1.68 ± 1.06 in LF, p < 0.0001), fasting blood glucose levels
(99.11 ± 7.84 in HEP, 85.11 ± 10.97 in LF, p < 0.0001), and
BMI (21.86 ± 1.88 in HEP, 24.94 ± 3.28 in LF, p = 0.019)
between subjects in the HEP and LF groups. There were
no significant differences in age, gender, FFA0 levels, and
SUVmax between the groups.
There were two polar map patterns of location of the
physiological myocardial uptake (grade 2, 3, or 4) in the
left ventricular wall from the data of healthy subjects as
shown in Figure 4: (1) a diffuse uptake and (2) basal
ring-like and/or lateral uptake. Healthy subjects of the
HEP group revealed diffuse uptake pattern in 31% (5/16)
and basal ring-like and/or lateral uptake pattern in 69%
(11/16, Table 2), whereas those of the LF group did diffuse
uptake pattern in 29% (2/7) and basal ring-like and/or
lateral uptake pattern in 71% (5/7, Table 3). Based on
the polar map patterns observed in healthy subjects, we
considered a diffuse uptake or basal ring-like and/orlateral uptake to be physiological in patients with suspected
or known cardiac sarcoidosis.
Regression trees in all healthy subjects (n = 37) showed
that the most significant factor that discriminated between
grade 1 physiological myocardial 18F-FDG uptake and
grade 2, 3, or 4 was ‘LF’. In subjects in the LF group, the
most significant discriminatory factor for grade 1 physio-
logical myocardial 18F-FDG uptake and grades 2, 3, or 4
was ‘FFA0’ ≥ 0.547 compared with ‘FFA0’ < 0.547.
Differences between HEP and LF and factors for inhibiting
physiological myocardial 18F-FDG uptake in patients with
known or suspected CS
Patient characteristics and blood sampling data for sub-
jects in the HEP and LF groups are summarized in Table 5.
Ninety-six and 69 18F-FDG PET scans were performed in
patients with HEP and LF, respectively. The mean fasting
time in the LF group was 20 h (range, 18 to 26 h). The
differences in physiological uptake (2.46 ± 1.33 in HEP,
1.48 ± 0.99 in LF; p < 0.0001), fasting blood glucose levels
(99.68 ± 14.12 in HEP, 92.80 ± 13.35 in LF, p = 0.002),
and FFA0 levels (0.81 ± 0.39 in HEP, 1.02 ± 0.41 in LF,
p = 0.001) were statistically significant. There were no
significant differences in age, gender, BMI, and use of
steroid therapy between the groups.
Table 3 Healthy volunteers with 18-hour fasting
No. Age (years) Gender BMI Fasting duration (h) FBG (mg/dL) FFA0 (mEq/L) Phy U SUVmax Polar map pattern
1 68 Male 27.4 18 86 0.56 1 3.54
2 64 Female 22.3 18 90 0.5 1 3.06
3 56 Male 22.5 16 87 0.63 3 7.23 Basal lateral
4 42 Male 27.1 23 88 0.24 4 20.35 Diffuse
5 64 Female 27.9 18 95 0.73 1 3.05
6 66 Male 21.7 17 74 1.31 1 2.71
7 39 Male 23.4 18 88 0.58 1 2.78
8 41 Male 27.4 18 92 0.52 2 5.05 Basal lateral
9 72 Female 19.8 18 100 0.41 2 3.3 Basal lateral
10 44 Female 24.2 18 78 0.72 4 6.88 Diffuse
11 68 Female 22.2 18 77 0.96 1 2.13
12 41 Female 19.0 18 75 0.273 2 3.62 Basal lateral
13 52 Male 28.6 18 78 0.539 3 5.9 Basal lateral
14 50 Female 23.3 22 78 0.725 1 1.84
15 40 Male 29.0 18.5 107 0.649 1 1.61
16 44 Male 21.8 18.5 68 0.731 1 1.55
17 63 Male 19.7 18 73 0.594 1 1.31
18 47 Male 25.4 18 79 0.872 1 1.48
19 55 Male 30.0 18 104 0.547 1 1.83
BMI, body mass index; FBG, fasting blood glucose; FFA0, free fatty acid at baseline (normal range; 0.10 to 0.81 mEq/L); Phy U, physiological uptake (grading scale)
1 to 4; SUVmax, maximal standard uptake value.
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important determinant of physiological uptake inhibition
(Table 6). Classification and regression trees revealed that
the most significant factor to determine between grade 1
physiological uptake and grades 2, 3, and 4 in all 165
patients was LF (Figure 5). In patients with LF, FFA0 ≥ 0.76
was a significant determinant of the inhibition of physio-
logical uptake. When a patient with LF had FFA0 ≥ 0.76,
the probability that physiological uptake would be inhibited
was approximately 91%.Table 4 Comparison of 18-h fasting with heparin loading
plus 12-h fasting in healthy subjects
HEP LF p value
N Average ± SD N Average ± SD
Age (year) 18 47.11 ± 12.53 19 53.47 ± 11.34 0.11
Gender 18 M/F = 10:8 19 M/F = 12:7 0.64
FBG 18 99.11 ± 7.84 19 85.11 ± 10.97 <0.0001***
FFA 18 0.64 ± 0.27 19 0.64 ± 0.24 0.94
BMI 18 21.86 ± 1.88 19 24.94 ± 3.28 0.019*
Phy U 18 3.17 ± 1.16 19 1.68 ± 1.06 <0.0001***
SUVmax 18 6.21 ± 3.64 19 4.17 ± 4.31 0.13
HEP, heparin loading plus 12-h fasting; LF; 16-h or more fasting; FBG, fasting
blood glucose (mg/dL); FFA, plasma free fatty acids (mEq/L); BMI, body mass
index; Phy U, physiological uptake grades 1 to 4; *p < 0.05, ***p < 0.001.Discussion
Myocardial uptake is heterogeneous, and the glucose
loading method is the standard protocol for detecting
viability using 18F-FDG PET [18-20]. On the other hand,
other methods attempt to detect inflammatory lesions in
CS. These methods include the LF method, which involves
a long fasting period before intravenous 18F-FDG injection
[11-13], the consumption of a fatty meal [14,15], and the
HEP method [4,5,9,10]. After heparin injection, plasma FFA
levels acutely increase [9], reducing glucose consumption in
the normal myocardium, and consequently this highlights,
the FDG uptake in inflammatory lesions. It is believed that
these methods result in high FFA levels, which inhibit
physiological myocardial uptake.
In the present study, we compared the physiological
uptake using the LF and HEP methods. We performed
cardiac 18F-FDG PET using the LF and HEP methods in
healthy subjects, and we observed that HEP did not
reduce the overall physiological uptake compared with
LF. Using the LF method, the physiological uptake was
inhibited more efficiently in subjects with higher plasma
FFA levels.
SUVmax was higher in patients in the HEP group than
in the LF group, and it was inversely correlated with the
FFA0 levels. Boden reported chronic increases in the
FFA levels; when elevated FFA levels are chronically






Figure 4 Polar maps of healthy volunteers with myocardial FDG uptake. There were two patterns of myocardial FDG uptake (grade 2, 3, or 4)
in healthy volunteers when they had preparation with 12-h fast plus heparin injection (HEP) or long fast (16 h or more, LF). The polar map patterns
include (1) a diffuse uptake pattern and (2) a basal ring-like and/or lateral uptake pattern.
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http://www.ejnmmires.com/content/4/1/1maintained, they cause peripheral (muscle) insulin resist-
ance, inhibiting insulin-stimulated glucose uptake and
glycogen synthesis [21-23]. FFA0 level reflects the chronic
state in an individual. When the FFA0 level is high,
physiological uptake of glucose in the myocardium is
reduced. In this study, we used a single injection of
heparin; thus, the FFA75 levels decreased after an ini-
tial increase in the FFA15 levels. That is a reason why
physiological FDG uptake was not inhibited enough in
HEP. Persistent FFA levels were inadequate in using a
single 50 IU/kg dose. A longer continuous infusion of
heparin may have been more successful. For anotherTable 5 Comparison between HEP and LF in patients with
known or suspected cardiac sarcoidosis
HEP LF p value
N Average ± SD N Average ± SD
Age (years) 96 57.19 ± 13.88 69 56.94 ± 13.16 0.91
Gender 96 M/F = 37:59 69 M/F = 17:52 0.06
FBG 96 99.68 ± 14.12 69 92.80 ± 13.35 0.002**
FFA 96 0.81 ± 0.39 69 1.02 ± 0.41 0.001**
BMI 96 22.37 ± 3.39 69 21.83 ± 3.08 0.28
Phy U 96 2.46 ± 1.33 69 1.48 ± 0.99 <0.0001***
Steroid use 96 19 69 14 0.98
HEP, heparin loading plus 12-h fasting; LF, 16-h or more fasting; FBG, fasting
blood glucose (mg/dL); FFA, plasma free fatty acids (mEq/L); BMI, body mass
index; Phy U, physiological uptake grades 1 to 4; ** p < 0.01; *** p < 0.001.reason, there may have been effect of different diets,
because the study subjects were not on a special diet
(low carbohydrates and high fat). The low-carbohydrate
and high-fat meal may help ensure an adequately high
FFA0 [15].
In all patients with known or suspected CS, LF was
the most important predictor as per logistic regression
and regression trees. For patients in the LF group, the
FFA0 levels were the most important factor, and the cutoff
value of FFA0 levels was 0.76. LF is therefore the most
important factor for inhibiting physiological uptake, and
when FFA0 levels are more than 0.76 mEq/L, physiological
uptake is likely to be efficiently inhibited. In addition to
the information of FFA levels, evaluation by polar map
patterns may facilitate in differentiating abnormal FDG
uptake from normal physiological uptake. A diffuse uptake
or basal ring-like and/or lateral uptake pattern may be
physiological in patients with suspected or known cardiac
sarcoidosis, because these patterns were observed in
healthy subjects.
In healthy subjects, the cutoff value of FFA0 levels was
0.55 mEq/L as per regression trees. However, there were
significant differences in the BMI of the healthy subjects
in the HEP and LF groups, and the healthy subjects had
a higher BMI than the CS patients. The cutoff value of
the FFA0 levels may therefore differ based on population
characteristics, such as BMI. When the FFA0 levels are
considered, LF is a more effective factor in inhibiting
physiological uptake.
Table 6 Multivariate predictors of physiological uptake grade 1 in patients with known or suspected cardiac sarcoidosis
Predictors Odds ratio 95% Confidence interval p value
Lower limit Upper limit
Age (per 1-year increase) 0.994 0.968 1.021 0.677
Female 1.624 0.840 3.940 0.130
BMI (per 1-kg/m2 increase) 1.090 0.976 1.224 0.133
FBG (per 1-mg/dL increase) 0.992 0.966 1.017 0.517
FFA0 (per 1-mEg/L increase) 2.415 0.914 7.075 0.089
LF (against HEP) 4.708 2.268 10.172 <0.0001***
BMI, body mass index; FBG, fasting blood glucose; FFA0, baseline plasma free fatty acid levels; LF, 16-h or more fasting before scan; HEP; heparin loading plus
12-h fasting; *** p < 0.001.
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http://www.ejnmmires.com/content/4/1/1One of the main limitations of the present study was
that it was a non-randomized study. Because there was a
noticeable difference in the inhibition of physiological
myocardial 18F-FDG uptake between HEP and LF in
healthy subjects and in patients with known or suspected
CS, we were ethically unable to plan a randomized study.
Before having conducted the study, we had supposed that
more than 18-h fast must be hard for the study subjects,
although we believed longer fast must be effective for
inhibiting physiological FDG uptake. We had therefore
expected the additional effects of heparin administration
on 12-h fast method. However, physiological FDG uptake
was not inhibited enough in HEP. After that, we experi-
enced a couple of healthy volunteers with 18-h fast or
more who showed FDG uptake was completely inhibited.
An 18-h fast was acceptable for them. In addition to
this experience, heparin use always takes a risk of
heparin-induced thrombocytopenia. Taken together, we18 h or more f
against hepari













No n=19 Yes n=5
(3/5, 60%)(0/19, 0%)
Figure 5 Regression trees determining the factors that inhibit physio
The numbers in parentheses indicate the number and percentage of patieplanned an 18-h fast study without heparin use. We
are uncertain whether additional benefit of heparin use
to inhibit physiological FDG uptake overcomes the risk
of heparin-induced thrombocytopenia or bleeding. In
addition, we did not analyze patients with diabetes melli-
tus. CS patients often have diabetic complications because
of steroid use. Evaluation of 18F-FDG PET images in CS
patients who use steroids and have diabetes could be
important and should thus be addressed in future studies.
The importance of diet followed by extended fasting
has been suggested. Cheng et al. found that a 15-h fast
with a low-carbohydrate diet had a much lower SUVmax
of 3.3 SUV (similar to liver and thus approximately 2 on
our visual scale) vs. a SUVmax of 6.2 in those that had an
unrestricted diet and fasted 12 h [24]. Kaneta et al.
found that there was no difference in myocardial uptake
compared to the length of fasting, but a higher uptake




















logical myocardial 18F-FDG uptake and their respective cutoffs.
nts with grade 1 physiological myocardial 18F-FDG uptake.
Morooka et al. EJNMMI Research 2014, 4:1 Page 10 of 11
http://www.ejnmmires.com/content/4/1/1control over intake than in an inpatient hospital food
setting [25]. Probably an optimal protocol for inhibiting
physiological uptake may be a combination of all tech-
niques, including a low-carbohydrate and high-fat diet,
long fast, and heparin use. Patient's risk and conditions
should be considered for the preparation, and long fast
(more than 18 h) is recommended in measuring serum
free fatty acid levels before scanning.
Conclusions
The effect of LF on the inhibition of physiological myocar-
dial 18F-FDG PET uptake was compared with the effects
of HEP in healthy subjects and patients with known or
suspected CS. Physiological myocardial uptake was more
efficiently inhibited in patients in the LF group compared
with in the HEP group. In addition, increased FFA levels
may be associated with the inhibition of physiological
myocardial uptake. Our data suggest that LF and monito-
ring FFA0 levels could be helpful in the interpretation of
18F-FDG PET images used to evaluate active lesions of CS,
resulting in improved diagnosis and management.
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